New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: Candidates for clinical development

Journal of Medicinal Chemistry

Volumn 41, Issue 18, 1998, Pages 3387-3401

  Bold, Guido ^a   Fässler, Alexander ^a   Capraro, Hans Georg ^a   Cozens, Robert ^a   Klimkait, Thomas ^a   Lazdins, Janis ^a   Mestan, Jürgen ^a   Poncioni, Bernard ^a   Rösel, Johannes ^a   Stover, David ^a   Tintelnot Blomley, Marina ^a   Acemoglu, Figan ^a   Beck, Werner ^a   Boss, Eugen ^a   Eschbach, Martin ^a   Hürlimann, Thomas ^a   Masso, Elvira ^a   Roussel, Serge ^a   Ucci Stoll, Katharina ^a   Wyss, Dominique ^a   Lang, Marc ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; CGP 75136; CGP 75176; CGP 75355; DIPEPTIDE DERIVATIVE; INDINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-HIV AGENTS; AZA COMPOUNDS; BIOLOGICAL AVAILABILITY; DIPEPTIDES; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MICROBIAL; FEMALE; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; INDINAVIR; MICE; MICE, INBRED BALB C; SAQUINAVIR; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 15144353143     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970873c     Document Type: Article

References (37)

1. Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A. F.; Scolnick, E. M.; Sigal, I. S. Active Human Immunodeficiency Virus Protease is Required for Viral Infectivity. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4686-4690.
2. (a) Steele, F. R. New Protease Inhibitors, with Combination Drug Therapy, and Early Intervention to Reduce 'Viral Load' Show Real Promise in Treating AIDS. Nature Med. 1996, 2, 257-258.
3. (b) Deeks, St. G.; Smith, M.; Holodniy, M.; Kahn, J. O. HIV-1 Protease Inhibitors: A Review for Clinicians. J. Am. Med. Assoc. (U.S.) 1997, 277, 145-153.
4. (c) Phillips, K. D. Protease Inhibitors: A New Weapon and a New Strategy Against HIV. J. Assoc. Nurses AIDS Care 1996, 7, 57-71.
5. (d) Boudes, P.; Geiger, J.-M. Les inhibiteurs de la protéase du VIH: revue générale. Thérapie (France) 1996, 51, 319-325.
6. For recent reviews, see: (a) Chrusciel, R. A.; Romines, K. R. Recent developments in HIV protease inhibitor research. Exp. Opin. Ther. Patents 1997, 7, 111-121. (b) Vacca, J. P.; Condra, J. H. Clinically effective HIV-1 protease inhibitors. Drug Discovery Today 1997, 2, 261-272. (c) Chong, K. T. Recent Advances in HIV-1 Protease Inhibitors. Exp. Opin. Invest. Drugs 1996, 5, 115-124. (d) Kempf, D. J.; Sham, H. L. HIV Protease Inhibitors. Curr. Pharm. Des. 1996, 2, 225-246. (e) Mansour, T. S. Emerging Anti-HIV Agents and Targets. Exp. Opin. Ther. Patents 1996, 6, 137-159. (f) Martin, J. A.; Redshaw, S.; Thomas, G. J. Inhibitors of HIV Proteinase. Prog. Med. Chem. 1995, 32, 239-287. (g) West, M. L.; Fairlie, D. P. Targeting HIV-1 Protease; a Test of Drug-design Methodologies. Trends Pharmacol. Sci. 1995, 16, 67-75. (h) De Clercq, E. Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections. J. Med. Chem. 1995, 38, 2491-2517. (i) Darke, P. L.; Huff, J. R. HIV Protease as an Inhibitor Target for the Treatment of AIDS. Adv. Pharmacol. 1994, 25, 399-454. (j) De Lucca, G. V.; Erickson-Viitanen, S.; Lam, P. Y. S. Cyclic HIV Protease Inhibitors Capable of Displacing the Active Site Structural Water Molecule. Drug Discovery Today 1997, 2, 6-18.
7. For recent reviews, see: (a) Chrusciel, R. A.; Romines, K. R. Recent developments in HIV protease inhibitor research. Exp. Opin. Ther. Patents 1997, 7, 111-121. (b) Vacca, J. P.; Condra, J. H. Clinically effective HIV-1 protease inhibitors. Drug Discovery Today 1997, 2, 261-272. (c) Chong, K. T. Recent Advances in HIV-1 Protease Inhibitors. Exp. Opin. Invest. Drugs 1996, 5, 115-124. (d) Kempf, D. J.; Sham, H. L. HIV Protease Inhibitors. Curr. Pharm. Des. 1996, 2, 225-246. (e) Mansour, T. S. Emerging Anti-HIV Agents and Targets. Exp. Opin. Ther. Patents 1996, 6, 137-159. (f) Martin, J. A.; Redshaw, S.; Thomas, G. J. Inhibitors of HIV Proteinase. Prog. Med. Chem. 1995, 32, 239-287. (g) West, M. L.; Fairlie, D. P. Targeting HIV-1 Protease; a Test of Drug-design Methodologies. Trends Pharmacol. Sci. 1995, 16, 67-75. (h) De Clercq, E. Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections. J. Med. Chem. 1995, 38, 2491-2517. (i) Darke, P. L.; Huff, J. R. HIV Protease as an Inhibitor Target for the Treatment of AIDS. Adv. Pharmacol. 1994, 25, 399-454. (j) De Lucca, G. V.; Erickson-Viitanen, S.; Lam, P. Y. S. Cyclic HIV Protease Inhibitors Capable of Displacing the Active Site Structural Water Molecule. Drug Discovery Today 1997, 2, 6-18.
8. For recent reviews, see: (a) Chrusciel, R. A.; Romines, K. R. Recent developments in HIV protease inhibitor research. Exp. Opin. Ther. Patents 1997, 7, 111-121. (b) Vacca, J. P.; Condra, J. H. Clinically effective HIV-1 protease inhibitors. Drug Discovery Today 1997, 2, 261-272. (c) Chong, K. T. Recent Advances in HIV-1 Protease Inhibitors. Exp. Opin. Invest. Drugs 1996, 5, 115-124. (d) Kempf, D. J.; Sham, H. L. HIV Protease Inhibitors. Curr. Pharm. Des. 1996, 2, 225-246. (e) Mansour, T. S. Emerging Anti-HIV Agents and Targets. Exp. Opin. Ther. Patents 1996, 6, 137-159. (f) Martin, J. A.; Redshaw, S.; Thomas, G. J. Inhibitors of HIV Proteinase. Prog. Med. Chem. 1995, 32, 239-287. (g) West, M. L.; Fairlie, D. P. Targeting HIV-1 Protease; a Test of Drug-design Methodologies. Trends Pharmacol. Sci. 1995, 16, 67-75. (h) De Clercq, E. Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections. J. Med. Chem. 1995, 38, 2491-2517. (i) Darke, P. L.; Huff, J. R. HIV Protease as an Inhibitor Target for the Treatment of AIDS. Adv. Pharmacol. 1994, 25, 399-454. (j) De Lucca, G. V.; Erickson-Viitanen, S.; Lam, P. Y. S. Cyclic HIV Protease Inhibitors Capable of Displacing the Active Site Structural Water Molecule. Drug Discovery Today 1997, 2, 6-18.
9. For recent reviews, see: (a) Chrusciel, R. A.; Romines, K. R. Recent developments in HIV protease inhibitor research. Exp. Opin. Ther. Patents 1997, 7, 111-121. (b) Vacca, J. P.; Condra, J. H. Clinically effective HIV-1 protease inhibitors. Drug Discovery Today 1997, 2, 261-272. (c) Chong, K. T. Recent Advances in HIV-1 Protease Inhibitors. Exp. Opin. Invest. Drugs 1996, 5, 115-124. (d) Kempf, D. J.; Sham, H. L. HIV Protease Inhibitors. Curr. Pharm. Des. 1996, 2, 225-246. (e) Mansour, T. S. Emerging Anti-HIV Agents and Targets. Exp. Opin. Ther. Patents 1996, 6, 137-159. (f) Martin, J. A.; Redshaw, S.; Thomas, G. J. Inhibitors of HIV Proteinase. Prog. Med. Chem. 1995, 32, 239-287. (g) West, M. L.; Fairlie, D. P. Targeting HIV-1 Protease; a Test of Drug-design Methodologies. Trends Pharmacol. Sci. 1995, 16, 67-75. (h) De Clercq, E. Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections. J. Med. Chem. 1995, 38, 2491-2517. (i) Darke, P. L.; Huff, J. R. HIV Protease as an Inhibitor Target for the Treatment of AIDS. Adv. Pharmacol. 1994, 25, 399-454. (j) De Lucca, G. V.; Erickson-Viitanen, S.; Lam, P. Y. S. Cyclic HIV Protease Inhibitors Capable of Displacing the Active Site Structural Water Molecule. Drug Discovery Today 1997, 2, 6-18.
10. For recent reviews, see: (a) Chrusciel, R. A.; Romines, K. R. Recent developments in HIV protease inhibitor research. Exp. Opin. Ther. Patents 1997, 7, 111-121. (b) Vacca, J. P.; Condra, J. H. Clinically effective HIV-1 protease inhibitors. Drug Discovery Today 1997, 2, 261-272. (c) Chong, K. T. Recent Advances in HIV-1 Protease Inhibitors. Exp. Opin. Invest. Drugs 1996, 5, 115-124. (d) Kempf, D. J.; Sham, H. L. HIV Protease Inhibitors. Curr. Pharm. Des. 1996, 2, 225-246. (e) Mansour, T. S. Emerging Anti-HIV Agents and Targets. Exp. Opin. Ther. Patents 1996, 6, 137-159. (f) Martin, J. A.; Redshaw, S.; Thomas, G. J. Inhibitors of HIV Proteinase. Prog. Med. Chem. 1995, 32, 239-287. (g) West, M. L.; Fairlie, D. P. Targeting HIV-1 Protease; a Test of Drug-design Methodologies. Trends Pharmacol. Sci. 1995, 16, 67-75. (h) De Clercq, E. Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections. J. Med. Chem. 1995, 38, 2491-2517. (i) Darke, P. L.; Huff, J. R. HIV Protease as an Inhibitor Target for the Treatment of AIDS. Adv. Pharmacol. 1994, 25, 399-454. (j) De Lucca, G. V.; Erickson-Viitanen, S.; Lam, P. Y. S. Cyclic HIV Protease Inhibitors Capable of Displacing the Active Site Structural Water Molecule. Drug Discovery Today 1997, 2, 6-18.
11. For recent reviews, see: (a) Chrusciel, R. A.; Romines, K. R. Recent developments in HIV protease inhibitor research. Exp. Opin. Ther. Patents 1997, 7, 111-121. (b) Vacca, J. P.; Condra, J. H. Clinically effective HIV-1 protease inhibitors. Drug Discovery Today 1997, 2, 261-272. (c) Chong, K. T. Recent Advances in HIV-1 Protease Inhibitors. Exp. Opin. Invest. Drugs 1996, 5, 115-124. (d) Kempf, D. J.; Sham, H. L. HIV Protease Inhibitors. Curr. Pharm. Des. 1996, 2, 225-246. (e) Mansour, T. S. Emerging Anti-HIV Agents and Targets. Exp. Opin. Ther. Patents 1996, 6, 137-159. (f) Martin, J. A.; Redshaw, S.; Thomas, G. J. Inhibitors of HIV Proteinase. Prog. Med. Chem. 1995, 32, 239-287. (g) West, M. L.; Fairlie, D. P. Targeting HIV-1 Protease; a Test of Drug-design Methodologies. Trends Pharmacol. Sci. 1995, 16, 67-75. (h) De Clercq, E. Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections. J. Med. Chem. 1995, 38, 2491-2517. (i) Darke, P. L.; Huff, J. R. HIV Protease as an Inhibitor Target for the Treatment of AIDS. Adv. Pharmacol. 1994, 25, 399-454. (j) De Lucca, G. V.; Erickson-Viitanen, S.; Lam, P. Y. S. Cyclic HIV Protease Inhibitors Capable of Displacing the Active Site Structural Water Molecule. Drug Discovery Today 1997, 2, 6-18.
12. For recent reviews, see: (a) Chrusciel, R. A.; Romines, K. R. Recent developments in HIV protease inhibitor research. Exp. Opin. Ther. Patents 1997, 7, 111-121. (b) Vacca, J. P.; Condra, J. H. Clinically effective HIV-1 protease inhibitors. Drug Discovery Today 1997, 2, 261-272. (c) Chong, K. T. Recent Advances in HIV-1 Protease Inhibitors. Exp. Opin. Invest. Drugs 1996, 5, 115-124. (d) Kempf, D. J.; Sham, H. L. HIV Protease Inhibitors. Curr. Pharm. Des. 1996, 2, 225-246. (e) Mansour, T. S. Emerging Anti-HIV Agents and Targets. Exp. Opin. Ther. Patents 1996, 6, 137-159. (f) Martin, J. A.; Redshaw, S.; Thomas, G. J. Inhibitors of HIV Proteinase. Prog. Med. Chem. 1995, 32, 239-287. (g) West, M. L.; Fairlie, D. P. Targeting HIV-1 Protease; a Test of Drug-design Methodologies. Trends Pharmacol. Sci. 1995, 16, 67-75. (h) De Clercq, E. Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections. J. Med. Chem. 1995, 38, 2491-2517. (i) Darke, P. L.; Huff, J. R. HIV Protease as an Inhibitor Target for the Treatment of AIDS. Adv. Pharmacol. 1994, 25, 399-454. (j) De Lucca, G. V.; Erickson-Viitanen, S.; Lam, P. Y. S. Cyclic HIV Protease Inhibitors Capable of Displacing the Active Site Structural Water Molecule. Drug Discovery Today 1997, 2, 6-18.
13. For recent reviews, see: (a) Chrusciel, R. A.; Romines, K. R. Recent developments in HIV protease inhibitor research. Exp. Opin. Ther. Patents 1997, 7, 111-121. (b) Vacca, J. P.; Condra, J. H. Clinically effective HIV-1 protease inhibitors. Drug Discovery Today 1997, 2, 261-272. (c) Chong, K. T. Recent Advances in HIV-1 Protease Inhibitors. Exp. Opin. Invest. Drugs 1996, 5, 115-124. (d) Kempf, D. J.; Sham, H. L. HIV Protease Inhibitors. Curr. Pharm. Des. 1996, 2, 225-246. (e) Mansour, T. S. Emerging Anti-HIV Agents and Targets. Exp. Opin. Ther. Patents 1996, 6, 137-159. (f) Martin, J. A.; Redshaw, S.; Thomas, G. J. Inhibitors of HIV Proteinase. Prog. Med. Chem. 1995, 32, 239-287. (g) West, M. L.; Fairlie, D. P. Targeting HIV-1 Protease; a Test of Drug-design Methodologies. Trends Pharmacol. Sci. 1995, 16, 67-75. (h) De Clercq, E. Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections. J. Med. Chem. 1995, 38, 2491-2517. (i) Darke, P. L.; Huff, J. R. HIV Protease as an Inhibitor Target for the Treatment of AIDS. Adv. Pharmacol. 1994, 25, 399-454. (j) De Lucca, G. V.; Erickson-Viitanen, S.; Lam, P. Y. S. Cyclic HIV Protease Inhibitors Capable of Displacing the Active Site Structural Water Molecule. Drug Discovery Today 1997, 2, 6-18.
14. For recent reviews, see: (a) Chrusciel, R. A.; Romines, K. R. Recent developments in HIV protease inhibitor research. Exp. Opin. Ther. Patents 1997, 7, 111-121. (b) Vacca, J. P.; Condra, J. H. Clinically effective HIV-1 protease inhibitors. Drug Discovery Today 1997, 2, 261-272. (c) Chong, K. T. Recent Advances in HIV-1 Protease Inhibitors. Exp. Opin. Invest. Drugs 1996, 5, 115-124. (d) Kempf, D. J.; Sham, H. L. HIV Protease Inhibitors. Curr. Pharm. Des. 1996, 2, 225-246. (e) Mansour, T. S. Emerging Anti-HIV Agents and Targets. Exp. Opin. Ther. Patents 1996, 6, 137-159. (f) Martin, J. A.; Redshaw, S.; Thomas, G. J. Inhibitors of HIV Proteinase. Prog. Med. Chem. 1995, 32, 239-287. (g) West, M. L.; Fairlie, D. P. Targeting HIV-1 Protease; a Test of Drug-design Methodologies. Trends Pharmacol. Sci. 1995, 16, 67-75. (h) De Clercq, E. Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections. J. Med. Chem. 1995, 38, 2491-2517. (i) Darke, P. L.; Huff, J. R. HIV Protease as an Inhibitor Target for the Treatment of AIDS. Adv. Pharmacol. 1994, 25, 399-454. (j) De Lucca, G. V.; Erickson-Viitanen, S.; Lam, P. Y. S. Cyclic HIV Protease Inhibitors Capable of Displacing the Active Site Structural Water Molecule. Drug Discovery Today 1997, 2, 6-18.
15. For recent reviews, see: (a) Chrusciel, R. A.; Romines, K. R. Recent developments in HIV protease inhibitor research. Exp. Opin. Ther. Patents 1997, 7, 111-121. (b) Vacca, J. P.; Condra, J. H. Clinically effective HIV-1 protease inhibitors. Drug Discovery Today 1997, 2, 261-272. (c) Chong, K. T. Recent Advances in HIV-1 Protease Inhibitors. Exp. Opin. Invest. Drugs 1996, 5, 115-124. (d) Kempf, D. J.; Sham, H. L. HIV Protease Inhibitors. Curr. Pharm. Des. 1996, 2, 225-246. (e) Mansour, T. S. Emerging Anti-HIV Agents and Targets. Exp. Opin. Ther. Patents 1996, 6, 137-159. (f) Martin, J. A.; Redshaw, S.; Thomas, G. J. Inhibitors of HIV Proteinase. Prog. Med. Chem. 1995, 32, 239-287. (g) West, M. L.; Fairlie, D. P. Targeting HIV-1 Protease; a Test of Drug-design Methodologies. Trends Pharmacol. Sci. 1995, 16, 67-75. (h) De Clercq, E. Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections. J. Med. Chem. 1995, 38, 2491-2517. (i) Darke, P. L.; Huff, J. R. HIV Protease as an Inhibitor Target for the Treatment of AIDS. Adv. Pharmacol. 1994, 25, 399-454. (j) De Lucca, G. V.; Erickson-Viitanen, S.; Lam, P. Y. S. Cyclic HIV Protease Inhibitors Capable of Displacing the Active Site Structural Water Molecule. Drug Discovery Today 1997, 2, 6-18.
16. (a) Zurer, P. Protease Inhibitors: Studies Probe HIV Resistance to Drugs. Chem. Eng. News 1996, 6.
17. (b) Mayers, D. L. Prevalence and Incidence of Resistance to Zidovudine and Other Antiretroviral Drugs. Am. J. Med. 1997, 102, 70-75.
18. (a) Navia, M. A.; Fitzgerald, P. M. D.; McKeever, B. M.; Leu, C.-T.; Heimbach, J. C.; Herber, W. K.; Sigal, I. S.; Darke, P. L.; Springer, J. P. Three-dimensional Structure of Aspartyl Protease from Human Immunodeficiency Virus HIV-1. Nature 1989, 337, 615-620.
19. (b) Wlodawer, A.; Miller, M.; Jaskólski, M.; Sathyanarayana, B. K.; Baldwin, E.; Weber, I. T.; Selk, L. M.; Clawson, L.; Schneider, J.; Kent, St. B. H. Conserved Folding in Retroviral Proteases: Crystal Structure of a Synthetic HIV-1 Protease. Science 1989, 245, 616-621.
20. (c) Lapatto, R.; Blundell, T.; Hemmings, A.; Overington, J.; Wilderspin, A.; Wood, St.; Merson, J. R.; Whittle, P. J.; Danley, D. E.; Geoghegan, K. F.; Hawrylik, St. J.; Lee, S. E.; Scheid, K. G.; Hobart, P. M. X-ray Analysis of HIV-1 Proteinase at 2.7 Å Resolution Confirms Structural Homology among Retroviral Enzymes. Nature 1989, 342, 299-302.
21. (a) Fässler, A.; Bold, G.; Lang, M.; Schneider, P. Pharmakologisch wirksame Hydrazinderivate und Verfahren zu deren Herstellung. EP-521827-A1, priority date July 3, 1991; publication date Jan 7, 1993.
22. (b) Fässler, A.; Rösel, J.; Grütter, M.; Tintelnot-Blomley, M.; Alteri, E.; Bold, G.; Lang, M. Novel Pseudosymmetric Inhibitors of HIV-1 Protease. Bioorg. Med. Chem. Lett. 1993, 3, 2837-2842.
23. (c) Sham. H. L.; Zhao, Ch.; Marsh, K. C.; Betebenner, D. A.; Lin, S.; McDonald, E.; Vasavanonda, S.; Wideburg, N.; Saldivar, A.; Robins, T.; Kempf, D. J.; Plattner, J. J.; Norbeck, D. W. Potent Inhibitors of the HIV-1 Protease with Good Oral Bioavailabilities. Biochem. Biophys. Res. Commun. 1995, 211, 159-165.
24. (d) Grobelny, D.; Chen, Q.; Tyssen, D.; Tachedjian, G.; Sebire, K.; Buchanan, L.; Birch, C. Antiviral activity of DG-35-VIII, a potent inhibitor of the protease of human immunodeficiency virus. Antiviral Chem. Chemother. 1997, 8, 99-106.
25. Fässler, A.; Bold, G.; Capraro, H.-G.; Cozens, R.; Mestan, J.; Poncioni, B.; Rösel, J.; Tintelnot-Blomley, M.; Lang, M. Aza-Peptide Analogues as Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors with Oral Bioavailability. J. Med. Chem. 1996, 39, 3203-3216.
26. Priestle, J. P.; Fässler, A.; Rösel, J.; Tintelnot-Blomley, M.; Strop, P.; Grütter, M. G. Comparative Analysis of the X-ray Structures of HIV-1 and HIV-2 Proteases in Complex with CGP 53820, a Novel Pseudosymmetric Inhibitor. Structure 1995, 3, 381-389.
27. 2 Group. J. Org. Chem. 1991, 56, 4280-4285.
28. Rutjes, F. P. J. T.; Teerhuis, N. M.; Hiemstra, H.; Speckamp, W. N. Synthesis of Cyclic α-Hydrazino Acid Derivatives via N-Acylhydrazonium Ions. Tetrahedron 1993, 49, 8605-8628.
29. Hydrogenation of 8e in the presence of Pd/C led to partial hydrogenolytical cleavage of the tetrazole ring, yielding N-1-(tert-butyloxycarbonyl)-N-2-(4-methylbenzyl)hydrazine. However, hydrogenation with Lindlar's catalyst gave pure 9e.
30. 1′ Phenyl Substituents: X-ray Crystal Structure Assisted Design. J. Med. Chem. 1992, 35, 1685-1701.
31. Luly, J. R.; Dellaria, J. F.; Plattner, J. J.; Soderquist, J. L.; Yi, N. A Synthesis of Protected Aminoalkyl Epoxides from α-Amino Acids. J. Org. Chem. 1987, 52, 1487-1492.
32. Irie, H.; Nakanishi, H.; Fujii, N.; Mizuno, Y.; Fushimi, T.; Funakoshi, S.; Yajima, H. Validity of Methoxycarbonyl as an N-Protecting Group in Peptide Synthesis: New Synthesis of MSH-Release Inhibiting Factor. Chem. Lett. 1980, 705-708.
33. (a) Jadhav, P. K.; Ala, P.; Woerner, F. J.; Chang, C.-H.; Garber, S. S.; Anton, E. D.; Bacheler, L. T. Cyclic Urea Amides: HIV-1 Protease Inhibitors with Low Nanomolar Potency against both Wild-Type and Protease Inhibitor Resistant Mutants of HIV. J. Med. Chem. 1997, 40, 181-191.
34. (b) Ala, P. J.; Huston, E. E.; Klabe, R. M.; McCabe, D. D.; Duke, J. L.; Rizzo, C. J.; Korant, B. D.; DeLoskey, R. J.; Lam, P. Y. S.; Hodge, C. N.; Chang, C.-H. Molecular Basis of HIV-1 Protease Drug Resistance: Structural Analysis of Mutant Proteases Complexed with Cyclic Urea Inhibitors. Biochemistry 1997, 36, 1573-1580.
35. (a) Capraro, H.-G.; Bold, G.; Fässler, A.; Cozens, R.; Klimkait, Th.; Lazdins, J.; Mestan, J.; Poncioni, B.; Rösel, J. L.; Stover, D.; Lang, M. Synthesis of Potent and Orally Active HIV-Protease Inhibitors. Arch. Pharm., Pharm. Med. Chem. 1996, 329, 273-278.
36. (b) Cozens, R. M.; Bold, G.; Capraro, H.-G.; Fässler, A.; Mestan, J.; Lang, M.; Poncioni, B.; Stover, D.; Rösel, J. L. Synthesis and pharmacological evaluation of CGP 57813 and CGP 61755, HIV-1 protease inhibitors from the Phe-c-Phe dipetidomimetic class. Antiviral Chem. Chemother. 1996, 7, 294-299.
37. Langer, K.; Mattay, J. Stereoselective Intramolecular Copper-(I)-Catalyzed [2+2]-Photocycloadditions. Enantioselective Synthesis of (+)- and (-)-Grandisol. J. Org. Chem. 1995, 60, 7256-7266.